Extra chromosome 21 reshapes development, not destiny alone
Down syndrome, or trisomy 21, stems from an extra full or partial chromosome 21. Parents are usually genetically typical; risk rises with maternal age from under 0.1% at twenty to about 3% at forty-five. Roughly one in a thousand births worldwide show the condition, and support—not a cure—shapes life quality.
British physician John Langdon Down lent the syndrome its modern name after earlier French descriptions. It is the most common chromosomal abnormality: about one in seven hundred U.S. births, with some 5.4 million people living with it globally in 2015. Most cases are full trisomy 21; rarer forms involve translocation or mosaicism. Chance, not parental behavior, drives occurrence. Prenatal screening plus diagnostic tests can identify it before birth; reported termination rates after diagnosis have ranged from about half to eighty-five percent depending on age and other factors.
Physical traits may include a recessed chin, folds at the inner eye corners, reduced muscle tone, a flattened bridge of the nose, and frequent tongue protrusion. About half experience obstructive sleep apnea; atlantoaxial joint instability affects roughly one to two percent and can threaten the spinal cord. Congenital heart disease, epilepsy, and immune vulnerability are more common. Adult intellectual abilities often resemble those of an eight- or nine-year-old, yet emotional and social awareness can be high, and milestones arrive later rather than never.
Education and care change outcomes: some children join typical classrooms, others need specialized support, and a few reach post-secondary study. In the United States about twenty percent of adults do some paid work, often with sheltered settings. Deaths fell from an estimated forty-three thousand in 1990 to twenty-seven thousand in 2015. The medical story is genetic; the human story is what communities build after the karyotype is known.
Source: Down syndrome
